IRANO response assessment for malignant glioma
Disappearance of all enhancing disease for ≥4 weeks; no new lesions; stable or improved T2/FLAIR; no more than physiological steroids; clinically stable or improved
≥50% decrease in the sum of biperpendicular diameters of enhancing disease for ≥4 weeks; no new lesions; stable or improved T2/FLAIR; stable or decreased steroid dose; clinically stable or improved
Does not qualify for complete response, partial response, or progressive disease; no new lesions; stable or improved T2/FLAIR; stable or decreased steroid dose; clinically stable or improved
≥25% increase in the sum of biperpendicular diameters of enhancing disease; or new lesions; or substantial worsened T2/FLAIR; or substantial clinical decline
References
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group Lancet Oncol. 2015 Nov;16(15):e534-e542
doi:
10.1016/S1470-2045(15)00088-1
close